Related Experiment Video
Updated: May 15, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Hemoglobin glycation index and cardiovascular outcomes in patients with coronary intermediate lesions: insights from
Fanzhou Zeng1, Chenxi Song1, Chunyue Wang1
1Cardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Cardiovascular Disease, Beijing, China.
Insights
High hemoglobin glycation index (HGI) significantly increases cardiovascular risk in patients with intermediate coronary lesions. This readily accessible biomarker can aid in risk stratification for better patient outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Biomarkers
Background:
- Intermediate coronary lesions pose residual cardiovascular risk despite being hemodynamically non-significant.
- Hemoglobin glycation index (HGI) is a novel marker reflecting glycemic variability.
- Assessing HGI's role in predicting outcomes for these patients is crucial.
Purpose of the Study:
- To evaluate the association between HGI and long-term adverse cardiovascular and cerebrovascular events (MACCEs).
- To determine if HGI can serve as a biomarker for risk stratification in patients with intermediate coronary lesions.
Main Methods:
- A cohort of 5932 patients with intermediate coronary lesions was stratified into three HGI tertiles.
- The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCEs).
- A median follow-up of 4.91 years was conducted to assess outcomes.
Main Results:
- A J-shaped association was observed between HGI and 5-year MACCEs after adjustment.
- Elevated HGI was a significant independent predictor of MACCEs (HR 1.138 per unit increase, P < 0.001).
- The High-HGI group exhibited a 76% higher risk of MACCEs compared to the Medium-HGI group (P=0.002).
Conclusions:
- HGI demonstrates a J-shaped association with MACCEs in patients with intermediate coronary lesions.
- High HGI is a robust independent predictor of adverse cardiovascular events.
- HGI is a potentially valuable and accessible biomarker for risk stratification in this patient population.
Aims:
Hemodynamically non-significant intermediate coronary lesions, though generally deferred from revascularization, still carry residual cardiovascular risk. Hemoglobin glycation index (HGI) is a novel indicator reflecting glycemic variability. This study aims to assess the association between HGI and long-term outcomes in these patients.
Methods:
We enrolled 5932 patients with intermediate lesions during 2017 and stratified them into three HGI tertiles. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCEs) over a median 4.91 - year follow-up .
Results:
During follow-up, 192 (3.2%) MACCEs occurred. A J-shaped association between HGI and 5-year MACCEs after adjustment was confirmed (P for non-linearity = 0.007), with an optimal inflection point of -0.24. Above this threshold, each 1-unit HGI increment significantly elevated MACCEs risk (HR 1.138, 95%CI 1.073-1.207, P < 0.001). The High-HGI group had a 76% higher MACCEs risk versus the Medium-HGI reference (HR 1.761, 95%CI 1.233-2.515, P = 0.002), whereas the Low-HGI group showed a non-significant trend toward higher risk.
Conclusions:
HGI has a J-shaped association with MACCEs in patients with intermediate lesions. While a high HGI is a robust independent predictor of adverse events, a low HGI represents a non-significant trend. HGI may serve as a readily accessible biomarker for risk stratification.
Related Concept Videos
Coronary Artery Disease I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease III: Clinical Manifestations
Hypertension III: Clinical Manifestations and Diagnostic Studies
Coronary Artery Disease II: Pathophysiology
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests